pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›REZENOPY
drug · small molecule
save

REZENOPY

updated 3mo ago
by $SCNX Scienture Holdings, Inc.🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval666 co-mentions · 280 sources
  • drugbuprenorphine ER454 co-mentions · 227 sources
  • drugBUPRENORPHINE HYDROCHLORIDE454 co-mentions · 227 sources
  • drugbuprenorphine454 co-mentions · 227 sources
  • drugSUBOXONE454 co-mentions · 227 sources
  • drugBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE454 co-mentions · 227 sources
  • drugSUBLOCADE454 co-mentions · 227 sources
  • drugBRIXADI454 co-mentions · 227 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 4 investigational indications.

targets

Opioid receptors; mu/kappa/delta

all catalysts(0)

nothing on the calendar yet

Trials studying REZENOPY

  • phase2A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockadenot yet recruitingn=16
  • phase1Pharmacodynamic Evaluation of Intranasal Nalmefenecompletedn=84
  • phase4A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Strokecompletedn=446
  • phase4Clinical Outcomes From Nalmefenewithdrawn

News(5)

  • Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring
    Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”
    fiercebiotech · 8d ago
  • Syphilis spreads while researchers contend with federal constraints and a drug shortage
    At the San Diego-Tijuana border, syphilis spreads while researchers contend with federal constraints and a drug shortage.
    stat · 14d ago
  • Trump administration will bring special ed to HHS
    Infant mortality rate dips, OTC naloxone options rise, and other health news from Morning Rounds
    stat · 1mo ago
  • FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
    The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergen…
    fda_press · 1mo ago
  • Are Republicans turning against medications for treating opioid addiction?
    Federal actions and proposals have reignited debate over methadone and buprenorphine, worrying addiction experts and patient groups.
    stat · 2mo ago
brand
REZENOPY
trade names
Evzio, Evzio (autoinjector), Kloxxado, Naloxone hydrochloride, Naloxone hydrochloride (autoinjector), Naloxone hydrochloride component of bunavail
generic
NALOXONE HYDROCHLORIDE
MOA
12.1 Mechanism of Action Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. Naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation, and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.
indication
1 INDICATIONS AND USAGE REZENOPY nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. REZENOPY nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. REZENOPY nasal spray is not a substitute for emergency medical care. REZENOPY nasal spray is an opioid antagonist for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ( 1 ) REZENOPY nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) REZENOPY nasal spray is not a substitute for emergency medical care. ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 50m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?